Effects of varying doses of fluticasone propionate on the physiology and bronchial wall immunopathology in mild-to-moderate asthma.

OBJECTIVES Inhaled corticosteroids (ICS) are typically associated with a flat dose-response curve when traditional efficacy values are examined (eg, FEV(1)). The aim of the present study was to investigate if a dose-response relationship exists for lung function and inflammatory cell numbers in bronchial biopsy specimens. METHODS Bronchial biopsy specimens were obtained from 36 patients randomized to receive 100 micro g, 500 microg, or 2,000 microg/d of fluticasone propionate (FP). Lung physiology and bronchial biopsies were performed at baseline and after 2 weeks of treatment. RESULTS Improvement in lung function and suppression of airway inflammation were optimal at a dose of 500 microg/d of FP. Significant changes from baseline following treatment were documented in FEV(1) (p = 0.02), forced expiratory flow (p = 0.002), FEV(1)/FVC (p = 0.007), provocative concentration of histamine causing a 20% fall in FEV(1) (PC(20)) [p = 0.02], T-cell numbers (p = 0.0005), activated eosinophils (p = 0.01), and numbers of macrophages (p = 0.01) in the group treated with 500 microg/d of FP. Comparison between groups administered different doses of FP failed to demonstrate a dose-response relationship for change from baseline in PC(20) (p = 0.43), any of the lung function parameters, T-cell numbers (p = 0.64), activated T cells (p = 0.46), eosinophils (p = 0.53), activated eosinophils (p = 0.48), or macrophage numbers (p = 0.68). CONCLUSION The apparent lack of a dose-response for ICS treatment in patients with asthma further validates the preferential use of add-on therapy over increasing the dose of ICS.

[1]  P. Sterk,et al.  The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. , 1990, The American review of respiratory disease.

[2]  P. Howarth,et al.  Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. , 1992, The American review of respiratory disease.

[3]  E. R. Mcfadden,et al.  Medical progress : asthma , 1992 .

[4]  K P Jones,et al.  Guidelines on the management of asthma. , 1993, Thorax.

[5]  J. Hébert,et al.  Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler. , 1993, Respiratory medicine.

[6]  J. Hébert,et al.  Evaluation of fluticasone propionate (500 μg day−1) administered either as dry powder via a Diskhaler® inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 μg day−1) administered by pressurized inhaler , 1993 .

[7]  R. Dockhorn,et al.  Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. , 1994, The Journal of allergy and clinical immunology.

[8]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[9]  E. Bateman,et al.  High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group. , 1995, The European respiratory journal.

[10]  W. Busse,et al.  Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. , 1995, American journal of respiratory and critical care medicine.

[11]  F. Hampel,et al.  Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. , 1996, Clinical therapeutics.

[12]  D. Kellerman,et al.  A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. , 1996, The Journal of asthma : official journal of the Association for the Care of Asthma.

[13]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[14]  A. Sheffer,et al.  Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. , 1996, The Journal of family practice.

[15]  B. Schmekel,et al.  Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma: a controlled study. , 1996, Thorax.

[16]  R. Nathan,et al.  A Comparison of Double-Strength Beclomethasone Dipropionate (84 μg) MDI With Beclomethasone Dipropionate (42 μ) MDI in the Treatment of Asthma , 1997 .

[17]  D. Kellerman,et al.  Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  R. Nathan,et al.  A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma. , 1997, Chest.

[19]  A. Casalini,et al.  Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. , 1997, American journal of respiratory and critical care medicine.

[20]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[21]  J. Faul,et al.  Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time , 1998, Thorax.

[22]  H. Boushey,et al.  Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation. , 1998, The European respiratory journal.

[23]  P. Barnes,et al.  Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. , 1998, The Journal of allergy and clinical immunology.

[24]  T L Petty,et al.  Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. , 1998, The Journal of allergy and clinical immunology.

[25]  D. Kellerman,et al.  Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. , 1998, The Journal of asthma : official journal of the Association for the Care of Asthma.

[26]  J. Lammers,et al.  Effects of fluticasone propionate and beclomethasone dipropionate on parameters of inflammation in peripheral blood of patients with asthma , 1998, Allergy.

[27]  E. Israel,et al.  Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients , 1999, BMJ.

[28]  J. Faul,et al.  The reproducibility of repeat measures of airway inflammation in stable atopic asthma. , 1999, American journal of respiratory and critical care medicine.

[29]  P. Barnes,et al.  Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma , 1999, Thorax.

[30]  E. Savilahti,et al.  Supplementary feeding in maternity hospitals and the risk of cow's milk allergy: A prospective study of 6209 infants. , 1999, The Journal of allergy and clinical immunology.

[31]  J. Fahy,et al.  Low- and high-dose fluticasone propionate in asthma; effects during and after treatment. , 2000, The European respiratory journal.

[32]  B. Lipworth,et al.  Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. , 2000, The American journal of medicine.

[33]  A. Herxheimer,et al.  Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. , 2001, BMJ : British Medical Journal.